Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
HKEX:2696
Holding HK:2696?
Track your performance easily
2696 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$11.20 - HK$23.45
Previous CloseHK$20.3
Volume230.80K
Average Volume (3M)279.90K
Market Cap
HK$11.03B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14.7
Beta0.66
Next Earnings
Mar 31, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.38
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume279,900
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shanghai Henlius Biotech, Inc. Class H News
PremiumCompany Announcements
Shanghai Henlius Advances Privatization Plans with Fosun
PremiumCompany Announcements
Shanghai Henlius Biotech Begins Phase 3 Trial for Cancer Therapy
PremiumCompany Announcements
Shanghai Henlius Gains FDA Nod for Denosumab Biosimilar
PremiumCompany Announcements
Shanghai Henlius Advances Phase 3 Cancer Trial Globally
PremiumCompany Announcements
Shanghai Henlius Biotech’s Privatization by Fosun Advances
PremiumCompany Announcements
Henlius Biotech’s HLX11 Meets Phase 3 Trial Goals
PremiumCompany Announcements
Henlius Biotech Advances Toward PrivatisationPremiumCompany Announcements
Henlius Biotech’s Drug Nears EU ApprovalOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
― Other Institutional Investors
99.86% Public Companies and
Individual Investors
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$11.20 and its highest was HK$23.45 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Currently, no data Available
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Mar 31, 2025 which is in 128 days.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Shanghai Henlius Biotech, Inc. Class H released its earnings results on Aug 26, 2024. The company reported HK$0.763 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.763.
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Overvalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.763 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.655%.
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
---
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.72%
12-Months-Change
Fundamentals
Return on Equity
31.16%
Trailing 12-Months
Asset Growth
3.62%
Trailing 12-Months
2696 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Yihai International Holding Ltd.
―
BeiGene Ltd
―
Lai Si Enterprise Holding Ltd.
―
Best Analysts Covering 2696
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+56.17%
reiterated a buy rating 7 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +56.17% per trade.
---